First day of trading in NeoDynamics’ shares and warrants on Spotlight Stock Market
Today, on December 7, 2018, the trading in NeoDynamics AB (publ)’s (”NeoDynamics”) shares and series TO 1 warrants starts at Spotlight Stock Market. The share is traded under the ticker “NEOD” and the share’s ISIN code is SE0011563410. The series TO 1 warrants are traded under the ticker “NEOD TO 1” and the warrant’s ISIN code is SE0011725605.
Issue of units before the listing
Ahead of the listing at Spotlight Stock Market, NeoDynamics has conducted an issue of units which has provided the company with approx. SEK 50,5 million before issue costs. The issue funds will finance the final development of the company’s NeoNavia product before launch. The total number of shares in NeoDynamics is 15.303.520 shares and the company’s share capital amounts to SEK 1.530.352,00. In addition, there are 3.080.000 outstanding series TO 1 warrants.
Sedermera Fondkommission has acted as financial advisor and issuing agency to NeoDynamics in connection with the issue of units and the listing on Spotlight Stock Market. Nordnet Bank AB is acting as Selling Agent in the issue of units.
For further information about the IPO and the listing, please contact:
Telephone: +46 (0) 40-615 14 10
For further information about NeoDynamics, please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ)
Telephone: +46 8 522 79 667
Jörgen Vrenning, CFO/IR NeoDynamics AB (publ)
Telefon: +46 708 519 648
Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, NeoDynamics have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.